Drug Dependence — Clinical Documentation Guide (2026)

🔍 Definition

Drug dependence (substance use disorder) is a chronic, relapsing brain disease characterized by compulsive drug seeking and use despite harmful consequences, driven by neurobiological changes in reward, stress, and inhibitory control circuits. Per the SAMHSA and American Psychiatric Association (APA), substance use disorders exist on a spectrum from mild to severe, formerly captured in DSM-IV as “abuse” and “dependence” — now unified under the DSM-5 framework as a single disorder with severity specifiers. For coding purposes, ICD-10-CM Chapter 5 (F10–F19) retains the use/abuse/dependence hierarchy per FY2026 ICD-10-CM Official Guidelines Section I.C.5.

The ICD-10-CM axis for this chapter organizes disorders by: (1) substance type (F10 alcohol through F19 other/multiple), (2) clinical severity within each substance (use, abuse, dependence, unspecified), and (3) associated complications (intoxication, withdrawal, mood disorder, psychotic disorder, etc.). Accurate code assignment requires the provider to explicitly document the specific substance, the level of use (use vs. abuse vs. dependence), and any active complications or comorbidities arising from the substance use.

🗂️ Alternative Terminology

Providers may use a wide variety of clinical, colloquial, and DSM-5/ICD terms. Coders and CDI specialists must recognize all of the following as potentially codeable diagnoses requiring clarification of severity and substance:

🩺 Signs & Symptoms

Clinical manifestations vary by substance but share common themes of tolerance, withdrawal, and loss of control. The following align with DSM-5 criteria (APA DSM-5) and are organized by domain:

General Substance Use Disorder Criteria (DSM-5 — 2 or more = mild; 4–5 = moderate; 6+ = severe)

• Taking larger amounts or over longer periods than intended
• Persistent desire or unsuccessful efforts to cut down/control use
• Great deal of time spent obtaining, using, or recovering from effects
• Craving or strong urge to use
• Failure to fulfill major role obligations (work, school, home)
• Continued use despite social/interpersonal problems caused by substance
• Important activities given up or reduced due to use
• Recurrent use in physically hazardous situations
• Continued use despite knowledge of persistent physical or psychological problems
• Tolerance: need for markedly increased amounts; diminished effect with same amount
• Withdrawal: characteristic syndrome; substance taken to relieve/avoid withdrawal

Substance-Specific Signs

• Alcohol (F10): Tremors, diaphoresis, tachycardia, hypertension, seizures (delirium tremens), hepatomegaly, peripheral neuropathy, blackouts
• Opioids (F11): Pinpoint pupils, respiratory depression, sedation, nausea/vomiting; withdrawal: rhinorrhea, lacrimation, piloerection, diarrhea, tachycardia, restlessness, COWS score >8
• Cannabis (F12): Conjunctival injection, increased appetite, dry mouth, impaired memory, amotivational syndrome
• Sedatives (F13): Ataxia, slurred speech, cognitive impairment; withdrawal: anxiety, insomnia, tremor, seizures — potentially life-threatening
• Cocaine/Stimulants (F14/F15): Tachycardia, hypertension, dilated pupils, paranoia, nasal septum perforation (cocaine), hyperthermia; crash: fatigue, depression, hypersomnia
• Nicotine/Tobacco (F17): Cravings, irritability, anxiety, difficulty concentrating, increased appetite on cessation; clinically silent long-term toxicity (COPD, CAD, lung cancer)
• Hallucinogens (F16): Perceptual distortions, flashbacks (HPPD), dissociation, autonomic arousal
• Inhalants (F18): Sudden sniffing death, perioral rash, chemical odor, encephalopathy

🧭 Differential Diagnosis

Distinguishing substance use disorders from related and comorbid conditions is critical for accurate ICD-10-CM coding. Many neuropsychiatric symptoms may be substance-induced or represent independent comorbidities — documentation must distinguish between the two per FY2026 Official Guidelines Section I.C.5.

📋 Clinical Indicators for Coders/CDI

The following indicators — when present in the medical record — suggest a codeable substance use disorder, a higher severity level, or a complication requiring additional codes. CDI specialists should review these triggers and query when documentation is absent or ambiguous.

🦴 Anatomy & Pathophysiology

Substance use disorders involve disruption of the brain’s mesolimbic dopamine reward pathway — colloquially called the “reward circuit” — involving the ventral tegmental area (VTA), nucleus accumbens, prefrontal cortex, and amygdala. Per NIDA (National Institute on Drug Abuse), all addictive substances trigger dopamine surges 2–10× greater than natural rewards, reinforcing drug-seeking behavior through neuroplastic changes.

Key Neurobiological Mechanisms by Substance Class

• Alcohol (F10): Enhances GABA-A receptor activity (inhibitory) and inhibits NMDA glutamate receptors (excitatory). Chronic use leads to compensatory upregulation of NMDA and downregulation of GABA, causing CNS hyperexcitability on withdrawal — the basis of alcohol withdrawal seizures and delirium tremens (F10.231, F10.232).
• Opioids (F11): Bind mu, kappa, and delta opioid receptors; suppress pain and activate reward via dopamine disinhibition. Chronic use causes receptor downregulation and desensitization → tolerance. Abrupt cessation unmasks noradrenergic hyperactivity (locus coeruleus) → withdrawal syndrome (F11.23).
• Cannabis (F12): THC binds CB1 cannabinoid receptors in prefrontal cortex, hippocampus, and cerebellum, disrupting memory consolidation and executive function. Long-term use associated with amotivational syndrome and cannabis use disorder in ~9% of users per NIDA cannabis research.
• Sedatives/Benzodiazepines (F13): Similar to alcohol — GABA potentiation. Withdrawal shares life-threatening features (seizures, delirium). Cross-tolerance with alcohol. Physiological dependence can develop within 4–6 weeks of daily therapeutic use.
• Cocaine/Stimulants (F14/F15): Block dopamine, norepinephrine, and serotonin reuptake transporters → massive monoamine surge. Methamphetamine also causes direct monoamine release. Chronic use depletes dopamine stores, causing anhedonia and depression in withdrawal (“crash”).
• Nicotine (F17): Binds nicotinic acetylcholine receptors (nAChR), particularly α4β2 in VTA → dopamine release. Neuroadaptation to nicotine is rapid; cessation triggers irritability, anxiety, difficulty concentrating, and intense craving (F17.213 withdrawal).
• Hallucinogens (F16): Classic psychedelics (LSD, psilocybin) act as 5-HT2A receptor agonists. Phencyclidine (PCP) is an NMDA receptor antagonist. Dissociative anesthetic at high doses.
• Inhalants (F18): Volatile hydrocarbons enhance GABA and inhibit NMDA activity; direct CNS, cardiac, hepatic, and renal toxicity. Sudden sniffing death via cardiac dysrhythmia.

💊 Medication Impact / Treatment

Pharmacological treatment of substance use disorders is evidence-based and FDA-approved for several substance classes. Medication-Assisted Treatment (MAT) for opioid use disorder represents the gold standard per SAMHSA MAT guidelines and ASAM Clinical Practice Guidelines.

FDA-Approved Pharmacotherapy by Substance

• Opioid Use Disorder (F11.2x):
  • Buprenorphine (Subutex)/Buprenorphine-Naloxone (Suboxone): Partial mu-opioid agonist; first-line MAT. HCPCS J0570–J0575 (buprenorphine formulations), J0592 (buprenorphine-naloxone/Suboxone). Code OUD (F11.2x) + G2086/G2087/G2088 for office-based OUD treatment (Medicare).
  • Methadone (opioid agonist): Full mu-agonist; dispensed at licensed OTPs (opioid treatment programs). HCPCS J3490 (unclassified). Both F11.20 (dependence, uncomplicated) + Z79.891 may apply when methadone serves dual purpose.
  • Naltrexone (Vivitrol): Opioid antagonist; blocks effects. Injectable monthly formulation. HCPCS J2315. Appropriate for sustained remission maintenance.
  • Naloxone (Narcan): Emergency opioid reversal — NOT maintenance treatment; for acute poisoning (T40.xx1A).
• Alcohol Use Disorder (F10.2x):
  • Naltrexone (oral/injectable): Reduces craving. HCPCS J2315 (Vivitrol IM).
  • Acamprosate (Campral): Reduces withdrawal-related dysphoria; restores GABA/glutamate balance. Oral only.
  • Disulfiram (Antabuse): Aversion therapy — causes acetaldehyde accumulation with alcohol ingestion → nausea, flushing, tachycardia.
  • Benzodiazepines (CIWA protocol): Management of acute alcohol withdrawal (F10.23x) — diazepam, lorazepam, chlordiazepoxide.
• Nicotine/Tobacco Use Disorder (F17.2xx):
  • Nicotine Replacement Therapy (NRT): Patches, gum, lozenge, inhaler, nasal spray — reduce withdrawal severity.
  • Varenicline (Chantix/Champix): Partial α4β2 nAChR agonist; most effective single agent per AHRQ Clinical Practice Guideline for Treating Tobacco Use.
  • Bupropion (Zyban): NDRI; reduces craving and withdrawal. Can combine with NRT.
• Stimulant/Cocaine Use Disorder: No FDA-approved pharmacotherapy; contingency management and CBT are mainstay per NIDA treatment principles.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The following summarizes key coding guidance from FY2026 ICD-10-CM Official Guidelines, Section I.C.5 (Mental, Behavioral and Neurodevelopmental Disorders) for substance use disorders:

1. Use/Abuse/Dependence Hierarchy (I.C.5.b.3)

• If both use and abuse are documented for the same substance → code abuse only
• If both abuse and dependence are documented for the same substance → code dependence only
• If both use and dependence are documented → code dependence only
• Assign the code that reflects the highest documented level of severity

2. Psychoactive Substance Use (I.C.5.b.1 — “Use” codes)

Use codes (F1x.9x) should be assigned only when documentation supports substance use (not abuse or dependence) that is clinically significant — i.e., the use affects management, treatment, or care during that encounter. Do not code substance use from social history alone if not addressed during the encounter.

3. In Remission Coding

• Early remission: 3–12 months without meeting SUD criteria (except craving) per DSM-5. Code F1x.11 (abuse, in early remission) or F1x.21 (dependence, in early remission).
• Sustained remission: 12+ months without meeting SUD criteria per DSM-5. Code F1x.11 (abuse) or F1x.21 (dependence, in sustained remission) — note: ICD-10-CM uses the same 4th/5th character for both early and sustained; clarification comes from provider documentation and DSM-5 criteria.
• Provider documentation must explicitly state “in remission” — do not infer from MAT alone.

4. Coding Concurrent Substance Use Disorders

When a patient has multiple substance use disorders, assign separate codes for each substance. Use F19 (other psychoactive substance) only when the substance is truly unknown or multiple substances cannot be individually identified.

5. Psychoactive Substance-Induced Disorders

When a substance use disorder causes a mental or behavioral complication (psychosis, mood disorder, anxiety, sleep disorder, sexual dysfunction, etc.), code the SUD with the appropriate complication 5th/6th character rather than using a separate F-code for the mental disorder. Example: F11.24 (opioid dependence with opioid-induced mood disorder) rather than F11.20 + F32.9.

6. Poisoning vs. Adverse Effect vs. Underdosing (T40.xx)

• Poisoning (intentional — 1st character = 1 or 2): Accidental (1), intentional self-harm (2), assault (3), undetermined (4)
• Adverse effect (5th character = 5): Correct drug, correct dose, properly administered; adverse reaction occurs
• Underdosing (5th character = 6): Taking less than prescribed; use Z91.14 (noncompliance with medication) as additional code
• Initial encounter: A; subsequent: D; sequela: S

7. Pregnancy and Substance Use

In pregnant patients, assign O99.32x (drug use complicating pregnancy/childbirth/puerperium) as the primary obstetric code, followed by the substance-specific F code. For newborns affected by maternal substance use: P96.1 (neonatal withdrawal symptoms from maternal use of drugs of addiction).

8. Tobacco Dependence — Critical Documentation Note

When a provider documents tobacco/nicotine dependence → assign F17.2xx (requires 5th character for product type and 6th character for complication). When only tobacco use is documented (no dependence) → assign Z72.0. The distinction carries significant clinical, risk-adjustment, and quality measure implications. Every smoking documentation encounter should trigger a CDI review per CDC tobacco control guidelines.

🔢 ICD-10-CM Code Set (FY2026)

All codes below are valid for FY2026 (effective October 1, 2025). Source: CMS FY2026 ICD-10-CM tabular list.

F10 — Alcohol-Related Disorders

F11 — Opioid-Related Disorders

F12–F19 — Other Substance-Related Disorders (Summary)

Associated / Supplementary Codes

🔎 Indexing

When indexing substance use disorders in the Alphabetic Index of the FY2026 ICD-10-CM, use these primary index terms and lead terms:

Note on Tabular Sequencing: For poisoning encounters, T40.xx codes are principal/first-listed, followed by the substance use disorder (F code) and any manifestation codes (e.g., respiratory failure J96.0x). For SUD management/detox encounters, the F code is principal. For MAT encounters, the OUD code (F11.20) is principal with Z79.891 as additional when applicable.

🏥 CPT (2026)

CPT codes for substance use disorder services are sourced from the AMA CPT 2026 Standard Edition. Behavioral health and substance use services may require appropriate modifier use, POS designation, and payer-specific coverage policies.

🧾 HCPCS (2026)

HCPCS Level II codes for substance use disorder treatment and medication-assisted treatment are sourced from the CMS HCPCS 2026 code set. These codes are essential for Medicare/Medicaid billing of OUD-specific services and drug formulations.

📚 AHA Coding Clinic (Recent Guidance)

The following AHA Coding Clinic references provide authoritative guidance on challenging substance use disorder coding scenarios. Coders should consult the full Coding Clinic text for complete guidance:

💰 HCC / Risk Adjustment (v28)

Under the CMS-HCC Model v28 (effective 2026), substance use disorders carry significant risk adjustment factor (RAF) weights. Accurate coding of the severity level (use vs. abuse vs. dependence) and complications directly impacts the RAF score and, consequently, capitation payments for Medicare Advantage plans.

✍️ CDI Query Templates

All queries below comply with AHIMA CDI Query Guidelines and ACDIS Practice Standards: non-leading, multiple-choice format, clinically based, and tied to documented clinical indicators.

🧑‍⚕️ Treatments (Clinical)

Treatment of substance use disorders is multimodal, integrating pharmacotherapy, behavioral interventions, and social support, guided by ASAM Clinical Practice Guidelines, SAMHSA treatment protocols, and the NIDA Principles of Drug Addiction Treatment.

ASAM Levels of Care

• Level 0.5: Early Intervention (SBIRT) — outpatient, <9 hours/week. CPT 99406–99409, G0396–G0397.
• Level 1: Outpatient Services — scheduled sessions, <9 hours/week. Individual/group therapy, MAT prescribing.
• Level 2.1: Intensive Outpatient (IOP) — 9–19 hours/week structured programming. H0015 per diem.
Level 2.5: Partial Hospitalization — 20+ hours/week medical monitoring. H0035 per diem.
• Level 3.1–3.7: Residential — medically monitored to managed inpatient detox/residential. H0018–H0019. MS-DRGs 895–897 (alcohol, drug abuse without/with CC/MCC).
• Level 4: Medically Managed Intensive Inpatient — hospital-based; MS-DRG 895 (drug/alcohol dependence, left AMA), 896 (with CC), 897 (without CC/MCC).

Behavioral Therapies

• Cognitive Behavioral Therapy (CBT): Identifies and modifies maladaptive thought patterns; evidence-based for cocaine, cannabis, alcohol. CPT 90834–90837.
• Motivational Interviewing (MI): Patient-centered counseling to resolve ambivalence about change; used in brief intervention (SBIRT) and ongoing treatment.
• Contingency Management (CM): Voucher/prize-based reinforcement of abstinence; most evidence for stimulant use disorders (no FDA-approved pharmacotherapy).
• 12-Step Facilitation (TSF): Structured engagement with AA/NA; group therapy. CPT 90853.
• Dialectical Behavior Therapy (DBT): Useful for borderline personality + SUD comorbidity.

Inpatient Detoxification Protocols

• Alcohol detox: CIWA-Ar scale-guided benzodiazepine taper; seizure precautions; IV thiamine 100 mg for Wernicke prevention; electrolyte management. MS-DRG 895–897.
• Opioid detox: Buprenorphine induction (COWS-guided, score ≥8–12 for induction), clonidine for autonomic symptoms, anti-diarrheal/anti-emetic supportive care. COWS protocol per SAMHSA buprenorphine guidance.
• Benzodiazepine detox: Long-acting benzo taper (diazepam/chlordiazepoxide) with slow reduction schedule; seizure monitoring — potentially life-threatening withdrawal identical to alcohol.
• Stimulant detox: Supportive only; manage depression, sleep disturbance, suicidal ideation during crash phase.

🎓 Patient Education / Summary

When providing patient education on substance use disorders, use accessible, non-stigmatizing language consistent with SAMHSA anti-stigma guidelines. Key patient education points:

• Substance use disorder is a medical condition, not a moral failing. Like diabetes or hypertension, it involves changes in brain chemistry that require treatment and ongoing management.
• Recovery is possible. Evidence-based treatments — including medications and therapy — are effective. Most people who engage in treatment improve significantly over time.
• Medication-Assisted Treatment (MAT) is not “just substituting one drug for another.” Buprenorphine, methadone, and naltrexone are FDA-approved, evidence-based treatments that reduce overdose deaths, cravings, and illicit drug use. Per SAMHSA MAT data, MAT reduces opioid use, criminal activity, and risk of HIV/Hepatitis C transmission.
• Tobacco dependence is among the most common and most treatable substance use disorders. Combination therapy (NRT + varenicline or bupropion) with behavioral support maximizes success rates. The AHRQ Treating Tobacco Use Guideline recommends offering cessation treatment at every clinical encounter.
• Naloxone (Narcan) is a life-saving medication that reverses opioid overdose. Patients with OUD and their household contacts should receive a naloxone prescription at every opportunity. Many states allow pharmacist dispensing without a prescription.
• If you or someone you know needs help: SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7, 365-day-a-year); SAMHSA Treatment Locator; findtreatment.gov.
• For coders and CDI specialists: Accurate documentation and coding of substance use disorders supports continuity of care, appropriate risk adjustment, and access to specialized treatment benefits for patients. Complete documentation — specifying substance, severity, complications, and treatment — serves the patient first and foremost.

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)